Lycopene for the Prevention and Treatment of Prostate Disease

  • Dragan IlicEmail author
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)


Benign prostatic hyperplasia (BPH) and prostate cancer are common diseases of the prostate gland. BPH is commonly treated by pharmaceutical products, which commonly improve symptoms but are often off-set by adverse events including erectile dysfunction, which affect quality of life. Similarly, a variety of treatment options exist for the treatment of prostate cancer. The applicability of these prostate cancer treatments is reliant on stage of disease. Whilst effectiveness of prostate cancer treatments may vary, common adverse effects include erectile dysfunction, incontinence and lower quality of life. Early evidence from systematic reviews has suggested that diet and lifestyle factors may be beneficial in reducing the risk of cancer. Lycopene, a member of the carotenoid family, found commonly in red pigmented fruit and vegetables has been established as having strong antioxidant and pro-oxidant properties. This chapter examines the current evidence on the use of lycopene as a preventive agent for prostate disease.


Prostate Cancer Erectile Dysfunction Benign Prostatic Hyperplasia Lower Urinary Tract Symptom Active Surveillance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ansari M, Gupta N (2003) A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 92:375–378PubMedCrossRefGoogle Scholar
  2. Bailey R, Gahche J, Lenito C et al (2011) Dietary supplement use in the United States, 2003–2006. J Nutr 141:261–266PubMedCrossRefGoogle Scholar
  3. Berry S, Coffey D, Walsh P, Ewing L (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479PubMedGoogle Scholar
  4. Chan J, Gann P, Giovannucci E (2005) Role of diet in prostate cancer development and progression. J Clin Oncol 23:8152–8160PubMedCrossRefGoogle Scholar
  5. Coyne K, Sexton C, Thompson C et al (2009) The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 104:352–360PubMedCrossRefGoogle Scholar
  6. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers M, Horneber M (2011) Selenium for preventing cancer. Cochrane Database Syst Rev. Issue 5. Art. no.: CD005195. doi:  005110.001002/14651858.CD14005195.pub14651852
  7. Etminan M, Takkouche B, Caamano-Isorna F (2004) The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomark Prev 13:340–345Google Scholar
  8. Haseen F, Cantwell M, O’Sullivan J, Murray L (2009) Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis 12:325–332PubMedCrossRefGoogle Scholar
  9. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU Guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRefGoogle Scholar
  10. Hoffman R, MacDonald R, Wilt T. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev. Issue 1. Art. no.: CD001987. doi:  10.1002/14651858.CD001987.pub2
  11. Ilic D, Misso M (2012) Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas 72:269–276PubMedCrossRefGoogle Scholar
  12. Ilic D, Forbes K, Hassad C (2011) Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev. Issue 11. Art. no.: CD008007. doi:  10.1002/14651858.CD008007.pub2)
  13. Ilic D, Neuberger M, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane Database Syst Rev. Issue 1. Art. no.: CD004720. doi:  004710.001002/14651858.CD14004720.pub14651853
  14. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRefGoogle Scholar
  15. Karas M, Amir H, Fishman D et al (2000) Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 26:101–111CrossRefGoogle Scholar
  16. Matsushima N, Shidoji Y, Nishiwaki S, Yamada T, Moriwaki H, Muto Y (1995) Suppression by carotenoids of microcystin-induced morphological changes in mouse hepatocytes. Lipids 30:1029–1034CrossRefGoogle Scholar
  17. McVary K, Roehrborn C, Avins A et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803PubMedCrossRefGoogle Scholar
  18. Porrini M, Riso P (2005) What are typical lycopene intakes? J Nutr 135:2042S–2045SPubMedGoogle Scholar
  19. Schwarz S, Obermuller-Jevic U, Hellmis E, Koch W, Jacobi G, Biesalski H (2008) Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 138:49–53PubMedGoogle Scholar
  20. Stratton J, Godwin M (2011) The effect of supplemental vitamins and minerals on the development of prostate cancer: a systematic review and meta-analysis. Fam Pract 28:243–252PubMedCrossRefGoogle Scholar
  21. Tacklind J, Fink H, MacDonald R, Rutks I, Wilt T (2010) Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. Issue 10. Art. no.: CD006015. doi:  10.1002/14651858.CD006015.pub3
  22. Wang X (2012) Lycopene metabolism and its biological significance. Am J Clin Nutr 96:1214S–1222SPubMedCrossRefGoogle Scholar
  23. Wertz K, Siler U, Goralczyk R (2004) Lycopene: modes of action to promote prostate health. Arch Biochem Biophys 430:127–134PubMedCrossRefGoogle Scholar
  24. Wilt T, Ishani A (1998) Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. Issue 1. Art. no.: CD001044. doi:  10.1002/14651858.CD001044
  25. Wilt T, MacDonald R, Hagerty K, Schellhammer P, Kramer B (2008) 5-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database of Systematic Reviews. ;Issue 2. Art. no.: CD007091. DOI:  10.1002/14651858.CD007091
  26. World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity and the prevention of cancer: A global perspective. AICR, Washington DCGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive MedicineMonash UniversityMelbourneAustralia

Personalised recommendations